Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

Core Insights - Legend Biotech is presenting six poster presentations on CARVYKTI at the upcoming Tandem Meetings, showcasing its efficacy, safety, and real-world outcomes in treating multiple myeloma [1][4]. Group 1: CARVYKTI Efficacy and Safety - CARVYKTI has treated over 10,000 patients globally, generating substantial clinical and real-world evidence for its use in multiple myeloma treatment [2]. - The therapy demonstrates consistent and durable efficacy and safety, particularly when administered earlier in the treatment journey, leading to meaningful quality-adjusted survival gains [3][4]. - CARVYKTI is the first and only BCMA-targeted CAR-T cell therapy approved for patients with multiple myeloma who have undergone at least one prior line of therapy, and it is now available in 14 countries [4]. Group 2: Poster Presentations Overview - The six poster presentations will cover various aspects of CARVYKTI, including quality-adjusted survival analysis, management of neurologic events, and the impact of bridging therapy on treatment outcomes [5][6]. - Specific topics include the characterization of neurologic events, the relationship between bridging therapy response and safety outcomes, and long-term progression-free survival benefits [5][6]. Group 3: Industry Context - Multiple myeloma is an incurable blood cancer with an estimated 35,000 new diagnoses and over 12,000 deaths in the U.S. in 2024, highlighting the critical need for effective treatments like CARVYKTI [58]. - Legend Biotech is positioned as a leader in cell therapy, focusing on maximizing patient access and therapeutic potential of CARVYKTI while expanding its pipeline of innovative treatments [59].